Cutaneous NeurofibromaPhase 1NCT04730583
Tolerability of Device Based Therapies for Neurofibromatosis Type 1 Cutaneous Neurofibromas
A Phase 1 study testing Kybella, 1064nm laser and 755nm Alexandrite Laser in people with Cutaneous Neurofibroma, run by Massachusetts General Hospital at 1 site in United States.
Trial summary
This study will evaluate the tolerability and effectiveness of three FDA-approved treatments in Neurofibromatosis Type 1 Cutaneous Neurofibromas. These treatments are: a 1064nm laser, a 755nm laser, and a Kybella injection. Each patient will have a treatment and a control site. Read more about this study
- Who is it for?
- Ages 18 to 85 years
- Conditions the study is for
- Cutaneous Neurofibroma
- What is being tested?
- Kybella, 1064nm laser and 755nm Alexandrite Laser
- Type of treatment
- Injection or infusion, Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 34 participants
- Where
- 1 siteUnited States
- Study dates
- 2 Jun 2021to 19 Apr 2024
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 85 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adult males and females ≥18 years of age
- Have a diagnosis of Neurofibromatosis Type 1
- Patients must be seeking treatment for cutaneous Neurofibromas
- Patients must have ≥ 6 paired cutaneous Neurofibromas (3 to be treated and 3 untreated) that are visible and measure between 2-4mm in size.
- Able and willing to comply with all visit, treatment and evaluation schedules and requirements
- Able to understand and provide written informed consent
- Access to a Smart Phone to be able to take and upload photographs to an application
Who cannot join
- Patients who are undergoing other treatment modalities or investigational agents for their cNF lesions
- Individuals who cannot give informed consent or adhere to study schedule
- Actively tanning during the course of the study
- Adverse reactions to compounds of any external agent (e.g., gels, lotions or anesthetic creams) required for use in the study, if no alternative to the said agent exists;
- Known allergy to injectable anesthetics or deoxycholic acid
- Any condition which, in the Investigator's opinion, would make it unsafe (for the participant or study personnel) to treat the participant as part of this research study;
- Pregnant females, due to possible discomfort with the procedure even though the procedure is localized and there is no new drug.
Trial locations and contacts
1 site in 1 country.
United States1 site
Wellman Center for Photomedicine, Massachusetts General Hospital
Boston, Massachusetts, 02114
About this study
This study will evaluate the tolerability and effectiveness of three FDA-approved treatments in Neurofibromatosis Type 1 Cutaneous Neurofibromas. These treatments are: a 1064nm laser, a 755nm laser, and a Kybella injection. Each patient will have a treatment and a control site.
- Conditions
- Cutaneous Neurofibroma
- Being tested
- Kybella, 1064nm laser, 755nm Alexandrite Laser
- Keywords
- Neurofibromatosis Type 1
- Medical subject headings
- Neurofibromatosis 1
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
KybellaDrug
Injection into the cutaneous Neurofibromas lesion
1064nm laserDevice
Pulse laser at a wavelength of 1064nm to the cutaneous Neurofibromas lesion
755nm Alexandrite LaserDevice
Pulse laser at a wavelength of 755nm to the cutaneous Neurofibromas lesion
| Study group | Role | What they receive |
|---|---|---|
| Kybella Injection | Active comparator | Not described Receives: Drug: Kybella |
| 1064nm laser | Active comparator | Not described Receives: Device: 1064nm laser |
| 755nm laser | Active comparator | Not described Receives: Device: 755nm Alexandrite Laser |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Device based treatment will be considered tolerable if <40% of participants treated have a >grade 2 adverse event (AE). A grade 2 AE is defined as an event that requires treatment.
Measured: 3 months after treatment
Secondary outcomes (2)
Patient Report Outcomes
Using questionnaires we will determine the patients reported outcomes
Measured: For the 12 months after treatment
Clinician Reported Outcomes
Using questionnaires we will determine the clinicians reported outcomes
Measured: For the 12 months after treatment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Jan 2021
- Study start2 Jun 2021
- Primary completion19 Apr 2024
- Study completion19 Apr 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cutaneous NeurofibromaStudies of the same condition, open and under way.
- More trials run by Massachusetts General HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 34 participants (actual)
Sponsor and investigators
- Lead sponsor
- Massachusetts General Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- Johns Hopkins University
- Responsible party
- Principal investigator, Richard Rox Anderson, MD, Massachusetts General Hospital
- Investigators
- R. Rox Anderson, MD, Principal investigator, Wellman Center for Photomedicine, Massachusetts General Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04730583
- Sponsor's protocol ID
- 2020P004137
- Status last verified
- Feb 2025
- First submitted
- 12 Jan 2021
- Last updated
- 21 Feb 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- Yes
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 21 Feb 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Tolerability of Device Based Therapies for Neurofibromatosis Type 1 Cutaneous Neurofibromas
- ClinicalTrials.gov ID
- NCT04730583
- Acronym / sponsor ID
- 2020P004137
- Conditions
- Cutaneous Neurofibroma
- Keywords
- Neurofibromatosis Type 1
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 34 participants (actual)
- Lead sponsor
- Massachusetts General HospitalUniversity, hospital or other
- Collaborators
- Johns Hopkins University
- Study start
- 2 Jun 2021 (actual)
- Primary completion
- 19 Apr 2024 (actual)
- Study completion
- 19 Apr 2024 (actual)
- First posted
- 29 Jan 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will evaluate the tolerability and effectiveness of three FDA-approved treatments in Neurofibromatosis Type 1 Cutaneous Neurofibromas. These treatments are: a 1064nm laser, a 755nm laser, and a Kybella injection. Each patient will have a treatment and a control site.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Kybella Injection | Active comparator | Drug: Kybella |
| 1064nm laser | Active comparator | Device: 1064nm laser |
| 755nm laser | Active comparator | Device: 755nm Alexandrite Laser |
Who may qualify
- Ages
- 18 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Adult males and females ≥18 years of age
- Have a diagnosis of Neurofibromatosis Type 1
- Patients must be seeking treatment for cutaneous Neurofibromas
- Patients must have ≥ 6 paired cutaneous Neurofibromas (3 to be treated and 3 untreated) that are visible and measure between 2-4mm in size.
- Able and willing to comply with all visit, treatment and evaluation schedules and requirements
Key exclusion criteria (7 listed)
- Patients who are undergoing other treatment modalities or investigational agents for their cNF lesions
- Individuals who cannot give informed consent or adhere to study schedule
- Actively tanning during the course of the study
- Adverse reactions to compounds of any external agent (e.g., gels, lotions or anesthetic creams) required for use in the study, if no alternative to the said agent exists;
- Known allergy to injectable anesthetics or deoxycholic acid
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| KybellaInjection into the cutaneous Neurofibromas lesion | Drug | Kybella Injection |
| 1064nm laserPulse laser at a wavelength of 1064nm to the cutaneous Neurofibromas lesion | Device | 1064nm laser |
| 755nm Alexandrite LaserPulse laser at a wavelength of 755nm to the cutaneous Neurofibromas lesion | Device | 755nm laser |
Primary outcome
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Time frame: 3 months after treatment
Device based treatment will be considered tolerable if <40% of participants treated have a >grade 2 adverse event (AE). A grade 2 AE is defined as an event that requires treatment.
2 secondary outcomes
Patient Report Outcomes
Time frame: For the 12 months after treatment
Clinician Reported Outcomes
Time frame: For the 12 months after treatment
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Feb 2025.
- Individual participant dataSharing planned: No
Related trials for Cutaneous Neurofibroma
RecruitingPhase 1
PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas
NF1 Mutation, Neurofibroma Plexiform
Active, not recruitingObservational study
Natural History Study of Cutaneous Neurofibromas in People With NF1
Neurofibromatosis Type 1, Neurofibromatosis 1
Active, not recruitingPhase 1/2
Doxycycline in Cutaneous Schwannoma (NF2)
Neurofibromatosis Type 2
RecruitingObservational study
Cutaneous and Mucosal Manifestations of Neurofribromatosis Type 2 in Children Under 15
Neurofibromatosis 2, Dermatology/Skin - Other
RecruitingPhase 1
Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1
NF1, Neurofibromatosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
R. Rox Anderson, MD principal investigator
Wellman Center for Photomedicine, Massachusetts General Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Kybella, 1064nm laser and 755nm Alexandrite Laser in people with Cutaneous Neurofibroma, run by Massachusetts General Hospital at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 21 Feb 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] (time frame: 3 months after treatment). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Feb 2025.